Poolbeg Pharma Stock
Poolbeg Pharma PLC
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- CEO
- Jeremy Skillington
- Employees
- 15
- Market cap
- £48 M
- IPO
- 19/07/2021
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the United Kingdom, focused on developing treatments for infectious diseases. Its pipeline features several key programs: POLB 001, a p38 MAP Kinase inhibitor intended for severe influenza; POLB 002, a pioneering, in-licensed RNA-based…
Poolbeg Pharma stock: price history
1D
-4.5%
1W
-8.7%
1M
-29.6%
6M
+37.0%
YTD
+57.5%
1Y
+77.5%
2Y
-21.3%
5Y
-38.5%
10Y
–
Next earnings date
Next earnings date
04/03/2027 (in 138 days)
Volatility around earnings
~2% weaker price swings than usual
Ask the agents about Poolbeg Pharma
Poolbeg Pharma stock metrics
P/E
-8.08
P/B
6.61
EV/EBITDA
-7.21
RETURN ON EQUITY
-28.9%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
67.3%
FLOAT SHARES
513,639,898
AVG. DAILY VOLUME (30D)
2,180,932
Comparable stocks
Frequently asked questions about Poolbeg Pharma stock
What does Poolbeg Pharma do?
Poolbeg Pharma PLC is a company in the Healthcare sector, Biotechnology industry, headquartered in United Kingdom.
The CEO is Jeremy Skillington, the company employs around 15 people.
The IPO was on 19/07/2021; the stock trades on LSE under the ticker POLB.L.
When does Poolbeg Pharma report next?
The next earnings date is 04/03/2027.
Around past earnings, price swings were roughly -2% stronger than usual.
Does Poolbeg Pharma pay a dividend?
No, Poolbeg Pharma currently does not pay a dividend.
Which stocks are comparable to Poolbeg Pharma?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Poolbeg Pharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess Poolbeg Pharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.